Back to Journals » OncoTargets and Therapy » Volume 9

In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: a retrospective cohort study

Authors Kuai J, Yang F, Li G, Fang X, Gao B

Received 21 December 2015

Accepted for publication 22 April 2016

Published 23 June 2016 Volume 2016:9 Pages 3763—3770

DOI https://doi.org/10.2147/OTT.S102909

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Geoffrey Pietersz


Jun Kuai,1 Fang Yang,1 Guang-Jun Li,2 Xiang-Jie Fang,3 Bao-Qin Gao2

1Department of Gastroenterology, 2First Department of General Surgery, 3Second Department of General Surgery, First Affiliated Hospital of Xin-Xiang Medical University, Henan, People’s Republic of China

Background: Conventional tumor managements have limited survival benefits and cause severely impaired immune function in patients with advanced gastric cancer (GC) whereas immunotherapies could restore antitumor immunity. This prospective cohort study was aimed at investigating the efficacy of in vitro-activated tumor-specific T lymphocytes combined with chemotherapy on the survival of patients with advanced GC.
Patients and methods: Two hundred and seventy-four postoperative patients were enrolled in this study to receive either activated T lymphocytes immunotherapy combining chemotherapy (71 patients) or only receive postoperative chemotherapy (203 patients). Overall survival was analyzed by the Kaplan–Meier with log-rank test and Cox’s regression methods.
Results: The immunotherapy prolonged 9.8-month median survival for advanced gastric cancer (29.70 vs 19.70 months, P=0.036). Furthermore, immunotherapy significantly benefited the survival of patients who underwent radical, palliative resection, and stage III malignancy. No serious adverse effect was observed in the immunotherapy group.
Conclusion: In vitro-activated tumor-specific T lymphocytes prolonged survival in patients with advanced GC.

Keywords: T lymphocytes, immunotherapy, survival, gastric cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]